You are here

Xi Shi


Wagner FF, Bishop JA, Gale JP, Shi X, et al. Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chem Biol. 2016;11(7):1952-1963.

Shi X, O’Neill MM, MacDonnell S, Brookes P, et al. The RSK inhibitor BIX 02565 limits cardiac ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther. 2016;21(2):177-186.

Chen S, Sanjana NE, Zheng K, Shalem O, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246-1260.

Shalem O, Sanjana NE, Hartenian E, Shi X, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-87.

Park SY, Shi X, Pang J, Yan C, Berk B. Thioredoxin-interacting protein mediates sustained VEGFR2 signaling in endothelial cells, which is necessary for angiogenesis. Arterioscler Thromb Vasc Biol. 2013;33(4):737-43.

Xi Shi, Ph.D.

Xi Shi is a research scientist I working in the Zhang Lab at the Broad Institute of MIT and Harvard. Her research topics include generating CRISPR-edited human embryonic stem cell (hESC) lines; differentiating hESCs to model human neuropsychiatric diseases; and characterizing induced human neurons by molecular profiling (pooled/single-cell RNA-Seq), biochemistry, and high-throughput electrophysiology using a multi-electrode array system (MEA). In addition, she is evaluating the in vivo gene editing efficiency of CRISPR in the mouse brain using the AAV delivery system. During her tenure at the Broad Institute, she has expanded her expertise in CRISPR-mediated genome editing, RNA-Seq, next-generation sequencing, neuron differentiation from hESCs, and electrical recording of neurons using MEA.

Shi joined the Broad Institute in 2013 as a postdoctoral associate in the Stanley Center for Psychiatric Research, and in 2016 moved into her current post. Prior to joining the Broad Institute, she worked as a research associate at Harvard University, where she used Drosophila as an animal model to understand genetic variation for drug response and to identify drug targets. She had previously worked as a postdoctoral associate in the Aab Cardiovascular Research Institute at the University of Rochester, studying signaling pathways regulated by thioredoxin interacting protein (TXNIP) in human umbilical vein endothelial cells.

Shi received her Ph.D. in pharmacology from the University of Rochester School of Medicine and Dentistry, where she investigated acute and chronic cardiac injury models in a mouse model while developing skills in mouse surgery, cell culture, and molecular/biochemical assays for signaling pathways. She also holds an M.S. in biology from Nanjing University and a B.S. in biology from Nanjing Normal University.

Contact Xi Shi via email at

February 2018